Life expectancy for people with metastatic or metastasized lung cancer is low. The 5-year survival rate for small cell lung cancer is 3%, and 8% for non-small cell lung cancer (NSCLC). 25-30% of ...

New research delves into the DNA details and chromatin structures that may predict prognosis in early-stage lung ...

Researchers from Touro University and Lovelace Biomedical are Developing an Innovative Treatment for Lung Cancer ...

Targeted therapy in metastatic non–small cell lung cancer had a 62% survival advantage, with an increase in the mean total cost by 2.45. Immunotherapy had a survival advantage of 48%, with an increase ...

Camrelizumab combo doubled the five-year survival rate in advanced squamous lung cancer, reducing mortality risk by 43%, in a ...

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

The report forecasts global market growth from $116.1 billion in 2024 to $168 billion by 2029 at a CAGR of 7.7%. Highlighting advances in immunotherapy, CAR-T cell therapy, and biomarker-based ...

The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso ...

"Lung cancer ranks third in terms of new cases but second in terms of mortality in Vietnam. Of the over 24,000 new cases ...

The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...